Great to have the Spark Valuation to give us some baseline figures.
I see any valuation as being a fluid object. Perhaps if the valuation was to be released after the top line data from Phase ! and the granting of ODD and other near term events, then we might be looking at launching the projections off a higher base to give us a different endpoint valuation.
And the assumption of MPL only capturing 10% of the addressable market seems a bit light on to me, especially if we become the new standard of care.
But it is informative to view the factors involved in a valuation.
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3, page-31
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $67.30M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 16.3¢ | $581.7K | 3.408M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 502428 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 40529 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
17.5¢ |
Change
-0.010 ( 3.15 %) |
||||
| Open | High | Low | Volume | ||
| 17.5¢ | 18.0¢ | 16.0¢ | 3492891 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| PAA (ASX) Chart |